In this research article from Bioanalysis learn more about the immunogenicity of anti-body drug conjugates. The research follows eight molecules across 11 clinical trials to evaluate the potentially increased immunogenicity risk of these multi-domain biotherapeutics compared with monoclonal antibodies.
Browsing: antibody–drug conjugates
Bioanalytical strategies for PK analysis of antibody–drug conjugate therapeutics using LC–HRMS & LC–MS/MS
Antibody–drug conjugates (ADCs) combine the best of two modalities: toxic efficacy and antibody specificity. This infographic describes various mass spectrometry-based strategies Frontage have successfully applied in the bioanalysis of ADCs for clinical and preclinical studies.
In this research article from Bioanalysis the authors discuss the quantitation of larger biotherapeutic proteins such as antibodies and antibody–drug conjugates compared with small molecules by LC–HRMS.
An author’s perspective: Wenying Jian on bioanalytical workflow for novel scaffold protein–drug conjugates
We talk to Wenying Jian about her work on the quantitation of total Centyrin protein using liquid chromatography–tandem mass spectrometry in this interview as part of our author’s perspective series.
Bioanalytical workflow for novel scaffold protein–drug conjugates: quantitation of total Centyrin protein, conjugated Centyrin and free payload for Centyrin–drug conjugate in plasma and tissue samples using liquid chromatography–tandem mass spectrometry
Alternative scaffold proteins have emerged as novel platforms for development of therapeutic applications. One such application is in protein–drug conjugates, which are analogous to antibody–drug conjugates. Find out more in this research article from Bioanalysis.